Process for the preparation of Cabozantinib and its pharmaceutically acceptable salts thereof
The present invention relates to an improved process for the preparation of N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide compound of formula-1 which is represented by the following structural formula:
1. A process for the preparation of Cabozantinib (formula-1),
comprising:
a) Reacting 4-chloro-6,7-dimethoxy-quinoline (formula-4),
with 4-aminophenol in the presence of a suitable base in a suitable solvent to provide 4-[(6,7-dimethoxy-4-quinolyl)oxy]aniline followed by treating the obtained compound with hydrochloric acid in a suitable solvent to provide 4-[(6,7-dimethoxy-4-quinolyl)oxy]aniline hydrochloride (formula-5),
b) reacting the resulting 4-[(6,7-dimethoxy-4-quinolyl)oxy]aniline hydrochloride (formula-5) with 1-[(4-fluorophenyl)carbamoyl]cyclopropane carboxylic acid (formula-2),
in the presence of a suitable coupling agent, suitable base and a suitable solvent to provide Cabozantinib (formula-1),
c) optionally, purifying the resulting Cabozantinib (formula-1) from a suitable solvent to provide pure Cabozantinib (formula-1).
2. The process of claim-1, wherein,
in step-a) the suitable base used is “alkali metal alkoxide”;
in step-b) the suitable coupling reagent is selected from hydroxybenzotriazole (HOBt), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCHCl), benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP), Bromo-trispyrrolidino phosphonium hexafluorophosphate (PyBrOP), 0-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU), 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), 1-[bis(dimethylamino) methylene]-1H 1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU), 1-cyano-Z-ethoxy-2-oxoethylidenaminooxy) dimethylamino-morpholino-carbeniumhexafluorophosphate (COMU) and tetramethyl fluoroformamidinium hexafluorophosphate (TFFH) or mixtures thereof in the presence of a base selected from diisopropyl ethylamine (DIPEA), N-methyl-morpholine (NMM), dimethylaminopyridine (DMAP) and pyridine; the suitable solvent used is “chloro solvent”;
in step-c) the suitable solvent is “alcoholic solvent”.
3. The process of claim 1 , wherein the process comprises:
a) Reacting 4-chloro-6,7-dimethoxy-quinoline (formula-4) with 4-aminophenol in the presence of potassium tert-butoxide in dimethylacetamide to provide 4-[(6,7-dimethoxy-4-quinolyl)oxy]aniline followed by treating the obtained compound with hydrochloric acid in methanol to provide 4-[(6,7-dimethoxy-4-quinolyl)oxy] aniline hydrochloride (formula-5),
b) reacting the 4-[(6,7-dimethoxy-4-quinolyl)oxy]aniline hydrochloride (formula-5) with 1-[(4-fluorophenyl)carbamoyl]cyclopropane carboxylic acid (formula-2) in the presence of EDC-HCl and DMAP in dichloromethane to provide Cabozantinib (formula-1),
c) purifying the Cabozantinib (formula-1) from methanol to provide pure Cabozantinib (formula-1).
4. The process of claim 1 , wherein the process further comprises a step of preparing the 1-[(4-fluorophenyl)carbamoyl]cyclopropane carboxylic acid (formula-2) used in step b), comprising:
treating methyl 1-(4-fluorophenylcarbamoyl) cyclopropanecarboxylate (formula-3),
with potassium hydroxide in water to provide 1-[(4-fluorophenyl)carbamoyl] cyclopropane carboxylic acid (formula-2).
5. A process for the preparation of 4-[(6,7-dimethoxy-4-quinolyl)oxy]aniline hydrochloride (formula-5), comprising reacting 4-chloro-6,7-dimethoxy-quinoline(formula-4) with 4-aminophenol in the presence of potassium tert-butoxide in dimethylacetamide to provide 4-[(6,7-dimethoxy-4-quinolyl)oxy]aniline, followed by treating the obtained compound with hydrochloric acid in methanol to provide 4-[(6,7-dimethoxy-4-quinolyl)oxy] aniline hydrochloride (formula-5).
6. A process for the preparation of Cabozantinib (formula-1), comprising reacting 4-[(6,7-dimethoxy-4-quinolyl)oxy]aniline hydrochloride (formula-5) with 1-[(4-fluorophenyl)carbamoyl]cyclopropane carboxylic acid (formula-2) in the presence of EDC-HCl and DMAP in dichloromethane to provide Cabozantinib (formula-1).
7. The process of claim 1 , wherein the process is a process for the preparation of Cabozantinib (S)-malate, and the process comprises:
i) Treating cyclopropane-1,1-dicarboxylic acid with thionyl chloride in tetrahydrofuran followed by methanol to provide 1-(methoxycarbonyl)cyclopropane carboxylic acid,
ii) treating the 1-(methoxycarbonyl)cyclopropanecarboxylic acid with thionyl chloride in tetrahydrofuran followed by reacting the obtained compound with 4-fluoroaniline in the presence of triethylamine to provide methyl 1-(4-fluorophenylcarbamoyl) cyclopropanecarboxylate (formula-3),
iii) treating the compound of formula-3 with a suitable base in a suitable solvent to provide 1-[(4-fluorophenyl)carbamoyl]cyclopropane carboxylic acid (formula-2),
a) reacting 4-chloro-6,7-dimethoxy-quinoline (formula-4) with 4-aminophenol in the presence of a suitable base in a suitable solvent to provide 4-[(6,7-dimethoxy-4-quinolyl)oxy]aniline, followed by treating the obtained compound with hydrochloric acid in a suitable solvent to provide 4-[(6,7-dimethoxy-4-quinolyl)oxy]aniline hydrochloride (formula-5),
b) reacting the 4-[(6,7-dimethoxy-4-quinolyl)oxy]aniline hydrochloride (formula-5) with the 1-[(4-fluorophenyl)carbamoyl]cyclopropane carboxylic acid (formula-2) obtained in step-(iii) in the presence of a suitable coupling agent, suitable base and a suitable solvent to provide Cabozantinib (formula-1),
c) optionally, purifying the Cabozantinib (formula-1) from a suitable solvent to provide pure Cabozantinib (formula-1),
d) treating the compound of formula-1 obtained in step-(b) or step-(c) with L-malic acid in a suitable solvent or mixture of solvents, followed by purifying the obtained compound in a suitable solvent or mixture of solvents to provide pure Cabozantinib (S)-malate.
8. The process of claim 7 , wherein the process comprises:
i) Treating the cyclopropane-1,1-dicarboxylic acid with thionyl chloride in tetrahydrofuran followed by methanol to provide 1-(methoxycarbonyl)cyclopropane carboxylic acid,
ii) treating the 1-(methoxycarbonyl)cyclopropanecarboxylic acid with thionyl chloride in tetrahydrofuran followed by reacting the obtained compound with 4-fluoroaniline in the presence of triethylamine to provide methyl 1-(4-fluorophenylcarbamoyl) cyclopropanecarboxylate (formula-3),
iii) treating the compound of formula-3 with potassium hydroxide in water to provide 1-[(4-fluorophenyl)carbamoyl]cyclopropanecarboxylic acid (formula-2),
a) reacting the 4-chloro-6,7-dimethoxy-quinoline (formula-4) with 4-aminophenol in the presence of potassium tert-butoxide in dimethylacetamide to provide 4-[(6,7-dimethoxy-4-quinolyl)oxy]aniline, followed by treating the obtained compound with hydrochloric acid in methanol to provide 4-[(6,7-dimethoxy-4-quinolyl)oxy] aniline hydrochloride (formula-5),
b) reacting the 4-[(6,7-dimethoxy-4-quinolyl)oxy]aniline hydrochloride (formula-5) with the 1-[(4-fluorophenyl)carbamoyl]cyclopropane carboxylic acid (formula-2) obtained in step-(iii) in the presence of EDC-HCl and DMAP in dichloromethane to provide Cabozantinib (formula-1),
c) purifying the Cabozantinib (formula-1) from methanol to provide pure Cabozantinib (formula-1),
d) treating the compound of formula-1 obtained in step-(c) with L-malic acid in n-butanol, followed by purifying the obtained compound in a solvent selected from methylisobutylketone (MIBK), n-heptane, methanol, tetrahydrofuran or mixtures thereof, to provide pure Cabozantinib (S)-malate.